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Honaucins AC were isolated from the cyanobacte-
rium Leptolyngbya crossbyana which was found
overgrowing corals on the Hawaiian coast. Honaucin
A consists of (S)-3-hydroxy-g-butyrolactone and
4-chlorocrotonic acid, which are connected via an
ester linkage. Honaucin A and its two natural analogs
exhibit potent inhibition of both bioluminescence,
a quorum-sensing-dependent phenotype, in Vibrio
harveyi BB120 and lipopolysaccharide-stimulated
nitric oxide production in the murine macrophage
cell line RAW264.7. The decrease in nitric oxide
production was accompanied by a decrease in the
transcripts of several proinflammatory cytokines,
most dramatically interleukin-1b. Synthesis of honau-
cinA, aswell as a number of analogs, and subsequent
evaluation in anti-inflammation and quorum-sensing
inhibition bioassays revealed the essential structural
features for activity in this chemical class and
providedanalogswithgreaterpotency inbothassays.
INTRODUCTION
Marine cyanobacteria have emerged as one of the richest sour-
ces of biologically active and structurally unique natural products
(Tidgewell et al., 2010). To date, there has been a strong focus on
the anticancer properties of cyanobacterial natural products,
perhaps due in part to funding priorities in biomedical research
and in part to a competitive advantage that these cytotoxic
metabolites may confer on their producers by deterring grazing
(Nagle and Paul, 1999). Regardless, it is likely that continued
interrogation of this natural-product-rich group will result in the
discovery of compounds with applications in other therapeutic
areas, such as management of inflammation, infection, and
neurological diseases.
Inflammation, in particular, is an attractive therapeutic target
due to its pervasive impacts on human health. In addition toChemistry & Biology 19,well-known chronic inflammatory disorders such as rheumatoid
arthritis and asthma, it is now recognized that many diseases not
previously thought to have an autoimmune basis do involve
inflammation, including cancer, heart diseases, skin diseases,
and disorders of the bowel (Grivennikov et al., 2010; Tousoulis
et al., 2011; Cheung et al., 2011). The ability to effectively treat
chronic inflammation is thus of great importance from the
perspective of both disease prevention and management as
well as reduction of health care costs. However, both of the
most commonly prescribed anti-inflammatory drug classes,
corticosteroids and nonsteroidal anti-inflammatory drugs
(NSAIDs), have undesirable side effects, including hypertension
and osteoporosis in the former case and gastrointestinal irrita-
tion and renal damage in the latter (Moghadam-Kia and Werth,
2010; Conaghan, 2011). Thus, an unmet medical demand exists
for novel anti-inflammatory agents that exert their effects
through different modes of action, and the natural products of
marine cyanobacteria may offer one possible source of such
compounds. Indeed, diverse marine organisms including marine
cyanobacteria have already been found to be sources of anti-
inflammatory metabolites that operate by novel mechanisms
(Terracciano et al., 2006; Gautam and Jachak, 2009; Villa and
Gerwick, 2010; Flachsmann et al., 2010).
The ability of small molecules to regulate quorum sensing (QS)
among pathogenic microorganisms represents a second
relatively unexplored area of drug discovery from marine cyano-
bacteria. QS is a population-density-based signaling process
through which prokaryotes coordinate diverse cellular
responses, including initiation of sporulation, swarming, hori-
zontal gene transfer, production or repression of virulence
factors and other secondary metabolites (to initiate pathogenic
or encourage mutualistic interactions), bioluminescence, and
biofilm formation (Pappas and Winans, 2003; Zhang et al.,
2002; Ni et al., 2009). QS is regulated by the production and
chemoreception of signaling molecules known as ‘‘autoin-
ducers.’’ When the density of an organism is sufficient for the
concentration of the autoinducer to surpass a threshold, gene
expression related to the above physiological responses is
triggered (Teng et al., 2011). Because QS can be a factor in the
pathogenicity of infectious microorganisms, inhibitors of this
process have garnered interest for their potential therapeutic589–598, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 589
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Structure-Activity Relationships of the Honaucinsapplications. QS inhibition of pathogenic microbes is especially
appealing, because it has the potential to impair the ability of
the pathogen to cause disease yet is not overtly lethal and thus
is unlikely to lead to the development of resistant phenotypes
(Galloway et al., 2011).
Several marine natural products that possess anti-inflamma-
tory properties have been found in marine invertebrates such
as corals and sponges, as well as in marine microorganisms
(Terracciano et al., 2006; Gautam and Jachak, 2009; Villa and
Gerwick, 2010; Flachsmann et al., 2010). With respect to marine
microorganisms, which in many cases are likely the actual
producers of the anti-inflammatory compounds isolated from
invertebrates, it is interesting to speculate that they may have
acquired the ability to produce anti-inflammatory compounds
in response to evolutionary pressures to overcome the innate
immune response mounted by their hosts (Villa and Gerwick,
2010; Ogier et al., 2010; McFall-Ngai et al., 2010).
Recent studies of bacterial communication and host-bacteria
interaction reveal that bacterial QS modulators have diverse
and sometimes contradictory effects on host cell physiology.
Under different circumstances, these can include either
inhibition or stimulation of the immune response, suggesting
that microbial QS signaling molecules are key modulators of
intra- and interkingdom interactions (Rumbaugh and Kauf-
mann, 2012). However, the exact relationship between bacte-
rial QS and host immunity is still unclear. Therefore, identifica-
tion of natural products with the capacity to modulate both
bacterial QS and host immune responses will provide useful
chemical tools for studying the relationships between these
two ecological phenomena and new lead molecules for drug
discovery.
In these regards, we have evaluated the extracts and metab-
olites of marine cyanobacteria as potential inhibitors of both
the mammalian innate immune system and bacterial QS
signaling. As a result, we describe here a group of newly discov-
ered natural products with both of these biological properties,
honaucins AC (13). These were isolated from the Hawaiian
cyanobacterium Leptolyngbya crossbyana, which was found
overgrowing coral reefs in the Honaunau Bay of Kona (Smith
et al., 2008). The structures of honaucins AC were elucidated
by standard spectroscopic techniques and confirmed by total
organic synthesis. Each of these new metabolites inhibited nitric
oxide (NO) production as well as the expression of selected
proinflammatory cytokines in RAW264.7 murine macrophage
cells stimulated with lipopolysaccharide (LPS). In addition, these
new natural products were found to inhibit QS-signaling-depen-
dent phenotypes in Vibrio harveyi BB120 and Escherichia coli
JB525. Synthesis of a minipanel of honaucin analogs was fol-
lowed by evaluation in the appropriate bioassays and revealed
several critical structural features for biological activity in this
structure class. Moreover, this effort resulted in the discovery
of honaucin derivatives with improved anti-inflammatory and
QS inhibitory properties.
RESULTS
Isolation and Structure Elucidation of Honaucins A–C
The colonial cyanobacterium Leptolyngbya crossbyana (HI09-1)
was collected in January 2009 by SCUBA from Honaunau reef590 Chemistry & Biology 19, 589–598, May 25, 2012 ª2012 Elsevieroff the island of Hawaii and extracted repetitively with 2:1
CH2Cl2-CH3OH to yield 1.7 g of crude extract. A portion of
the organic extract (1.4 g) was subjected to silica gel
vacuum-liquid chromatography (VLC) using a stepwise gradient
of hexanes/EtOAc/MeOH to produce nine fractions (AI).
Fraction E, eluting with 40% hexanes in EtOAc, was found to
potently inhibit production of NO in LPS-stimulated macro-
phages. This fraction was subjected to bioactivity-guided
fractionation using silica Sep-Pak chromatography and
reverse-phase high-performance liquid chromatography (RP
HPLC) to afford three pure anti-inflammatory compounds,
honaucins A (1, 5.4 mg, 0.39%), B (2, 1.4 mg, 0.10%), and C
(3, 1.1 mg, 0.08%).
Honaucin A (1) was obtained as a colorless oil and high-reso-
lution electrospray ionization mass spectroscopy (HR ESIMS)
showed a molecular ion cluster at m/z 205.0262/207.0240 at
a ratio of 3:1, indicating the presence of one chlorine atom (Fig-
ure S1 available online). The molecular formula of 1 was deter-
mined as C8H9ClO4 by HR ESI time-of-flight (TOF) MS
(HR ESITOFMS) ([M + H]+ m/z 205.0262), and the infrared (IR)
spectrum displayed absorption bands at 1784 and 1724 cm1
for the presence of g-lactone and a,b-unsaturated ester
functionalities. The 1H and 13C NMR spectra of 1 displayed
two downfield quaternary carbons (dC 174.5 and 165.0), two
olefinic protons (dH 7.06 and 6.13), an O-substituted methine
(dH 5.53), and an O-substituted methylene (dH 4.55 and 4.42)
(Table 1; Figure S1). NMR data from gradient correlation
spectroscopy (gCOSY), heteronuclear single-quantum coher-
ence, and heteronuclear multiple-bond coherence (gHMBC)
experiments allowed construction of b-O-substituted g-butyro-
lactone and 4-chlorocrotonic acid moieties. Finally, a gHMBC
correlation from H-3 to C-10 revealed a connection between
these partial structures, thus providing the planar structure of
honaucin A (1) (Figure 1).
Honaucin B (2) showed an isotope pattern similar to that of 1
by positive-ion HR ESITOFMS ([M + Na]+ m/z 273.0499), indi-
cating a molecular formula of C10H15ClO5 (Figure S2). The IR
spectrum of 2 displayed absorption bands at 3454, 1724, and
1659 cm1, indicating the presence of alcohol, a,b-unsaturated
ester, and isolated ester functionalities, respectively. The 1H
and 13C NMR spectra of 2 showed several resonances similar
to those in 1 (Table 1; Figure S2), thus confirming the presence
of 4-chlorocrotonic acid and a 3,4-di-O-substituted butanoic
acid moiety (Figure 1). A gHMBC correlation from H-4 to C-10
indicated an ester linkage between these positions, whereas
a correlation from H-5 to C-1 indicated that an ethyl group was
linked to C-1 via an ester bond.
Honaucin C (3,m/z 259.0346 for C9H13ClO5) also displayed an
isotope pattern consistent with one chlorine atom by positive-ion
HR ESITOFMS (Figure S3). The one- and two-dimensional (2D)
NMR spectra of 3 were almost identical to those of 2, although
the methyl triplet (H3-6, dH 1.28) and the methylene (H2-5, dH
4.18) in the ethyl group in 2 were replaced by a methyl singlet
(H3-5, dH 3.74) in 3 (Table 1; Figure S3). Finally, gHMBC correla-
tions from H-5 to C-1 and from H-4 to C-10 led to the planar
structure of honaucin C (3).
The absolute configuration at C-3 in 1 was determined
as S by comparing the optical rotation of 1 ([a]D
22 80.5)
with literature values of (R/S)-3-hydroxy-g-butyrolactoneLtd All rights reserved
Table 1. NMR Spectroscopic Data for Honaucin A–C in CDCl3
Honaucin A (1) Honaucin B (2) Honaucin C (3)
Position dC, Multi
dH, Multi
(J in Hz) COSY HMBCa dC, Multi
dH, Multi
(J in Hz) COSY HMBCa dC, Multi
dH, Multi
(J in Hz)
1 174.5, qC 172.2, qC 172.2, qC
2a 34.8, CH2 2.91, dd
(18.5, 6.7)
2b, 3 1, 4 38.0, CH2 2.57, s 3 1, 3 38.0, CH2 2.59, s
2b 2.67, d (18.5) 2a 1, 3, 4 2.56, d (3.46) 3 2.57, d (2.82)
3 70.3, CH 5.53, t (5.7) 2a, 4a 1, 4, 10 66.5, CH 4.32, m 2, 4 2, 4 66.5, CH 4.31, m
3-OH 3.14, brs 4 3.08, brs
4a 73.1, CH2 4.55, dd
(11.1, 4.7)
3, 4b 67.4, CH2 4.22, m 3 2, 3 67.4, CH2 4.21, m
4b 4.42, d (11.1) 4a 1, 2, 3
5 61.3, CH2 4.18, m 6 1 61.3, CH3 3.74, s
6 14.4, CH3 1.28, t (6.70) 5 5
10 165.0, qC 165.7, qC 165.7qC
20 122.9, CH 6.13, d (15.4) 30, 40 10, 30, 40 123.6, CH 6.16, d (15.4) 30, 40 10, 30, 40 123.6, CH 6.16, d (15.2)
30 144.1, CH 7.06, dt
(15.4, 5.9)
20, 40 10, 20, 40 142.9, CH 7.04, dt
(15.3, 5.9)
20, 40 10, 20, 40 142.9, CH 7.03, dt
(15.3, 5.8)
40 42.5, CH2 4.20, d (5.9) 30 10, 20, 30 42.6, CH2 4.19, m 30 20, 30 42.6, CH2 4.16, m
Measured at 600 MHz for 1H NMR and 150 MHz for 13C NMR.
aFrom 1H to the indicated 13C.
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Figure 1. Structures of Honaucins A–C
(A) Structures of honaucins AC (13).
(B) Structure elucidation of 1 and 2 based on NMR data.
See also Figures S1, S2, and S3.
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total synthesis of honaucin A, as well as its C-3 epimer
(17). Synthetic ()-honaucin A was prepared by Steglich
esterification of 4-chlorocrotonic acid (7) and (S)-3-hydroxy-g-
butyrolactone (4) (see Supplemental Experimental Procedures).
Similarly, epi-honaucin A (17) was synthesized from 4-chlorocro-
tonic acid (7) and (R)-3-hydroxy-g-butyrolactone (5). Synthetic
honaucin A was found to have a specific rotation of 77.5,
similar to that of the natural compound, whereas epi-honaucin
A (17) showed a specific rotation of +66.0. The absolute con-
figuration at C-3 in metabolites 2 and 3 was also determined
as S by comparing the specific rotations of 2 and 3 with the
literature value for the 4-O-tritylated derivative of ethyl (S)-3,4-
dihydroxybutanoate (Prasad et al., 1990).
Anti-Inflammatory Activity of Honaucins A–C
The degree of NO production in LPS-stimulated macrophages
provides a measurement of induced inflammation via the
activation of TLR4, followed by intracellular signaling via the
MyD88-dependent and MyD88-independent pathways and
the subsequent activation of the inducible nitric oxide synthase
gene (iNOS). We exploited these pathways in an initial pheno-
typic screen to assess the anti-inflammatory potential of
honaucins AC (13). NO production by LPS-stimulated
RAW264.7 murine macrophages was inhibited by compounds
13 with half-maximal inhibitory concentration (IC50) values of
4.0, 4.5, and 7.8 mM, respectively. By contrast, the IC50 value
for the cytotoxicity of honaucin A in the cells was greater
than 49 mM, giving a greater than 10-fold therapeutic window
between its NO inhibitory effect and cytotoxicity (Figure 2A;
Table 2).
To determine whether decreased NO production in the pres-
ence of honaucin A (1) was due to changes at the mRNA levelChemistry & Biology 19,or through radical oxygen scavenging, the antioxidant activity
of honaucin A was evaluated. However, no antioxidant activity
was observed up to 146 mM (Figure S4). Quantitation of the
transcript levels of key proinflammatory cytokines TNF-a,
IL-1b, IL-6, and iNOS in honaucin-A-treated versus untreated
LPS-stimulated RAW 264.7 cells was accomplished by quantita-
tive real-time polymerase chain reaction. Cells treated with
compound 1 had reduced transcript levels of all four cytokines
after 6 hr of treatment (reduction in transcripts of TNF-a, IL-1b,
IL-6 and iNOS were 9.3, 154.6, 19.0, and 11.8 fold,
respectively; Figure 2B).589–598, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 591
Figure 2. Biological Properties of Honaucins A–C
Error bars indicate the mean ± SD for n = 3.
(A) Inhibition of LPS-stimulated NO production on murine
macrophages.
(B) Downregulation of proinflammatory cytokines in LPS-
stimulatedmurinemacrophages by honaucin A (*p < 0.002
compared to LPS treatment alone).
(C) Inhibition of QS signaling in V. harveyi BB120.
(D) Inhibition of QS signaling in E. coli JB525.
See also Figure S4.
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Honaucins AC (13) were also screened for inhibition of QS-
regulated phenotypes in two different bacterial species, in part
due to the structural resemblance of honaucins AC to other
small lactone microbial signaling molecules. The wild-type strain
V. harveyi BB120 uses QS to regulate various phenotypes,
including bioluminescence (Henke and Bassler, 2004). Chemical
communication by V. harveyi is accomplished via three parallel
signaling pathways that utilize the autoinducers HA1-1, CAI-1,
and AI-2, respectively (Henke and Bassler, 2004). In the HAI-1
system, membrane-bound histidine kinase (LuxN-type) proteins
detect the native autoinducer 3-hydroxybutanoyl-L-homoserine
lactone. These are detected on the cell surface and information
is relayed into the cell via an intracellular signaling cascade
(Freeman et al., 2000; Swem et al., 2008, 2009). Genetic knock-
outs of the HAI-1 system display a 99.9% reduction in biolumi-
nescence (Henke and Bassler, 2004). All three natural honaucins
(13) demonstrated a dose-dependent inhibition of biolumines-
cence with IC50 values of 5.6, 17.6, and 14.6 mM, respectively
(Figure 2C), thus indicating the capacity of the honaucins to
antagonize this QS system. The g-butyrolactone functionality is
not an essential feature for inhibition of QS-mediated biolumi-
nescence in V. harveyi BB120, although it does have an impact
on potency.
A second reporter strain, E. coli strain JB525, was used to
further test for anti-QS activity of the honaucins (Andersen
et al., 2001). This strain has been engineered to produce the
V. fischeri LuxR receptor for acyl homoserine lactones (AHLs).
In contrast to the HAI-1 system of V. harveyiwhere the AHL binds
to a membrane bound receptor, the AHL in V. fisheri diffuses into
the cell to bind its cytoplasmic receptor for QS initiation (Ander-
sen et al., 2001; Swem et al., 2009). Once activated by exoge-
nously supplied autoinducer (3-oxo-hexanoyl homoserine
lactone, OHHL), LuxR positively affects expression of a luxI
promoter that initiates production of an unstable green fluores-
cent protein (GFP). Thus, measurement of GFP fluorescence592 Chemistry & Biology 19, 589–598, May 25, 2012 ª2012 Elsevier Ltd All rights resereflects the quantity of LuxR with bound
AHL (Andersen et al., 2001). Honaucin A (1)
inhibited production of GFP in E. coli JB525 in
a dose-dependent manner with an IC50 value
of 38.5 mM (Figure 2D). Honaucins B (2)
and C (3) were essentially inactive in this
assay (IC50 values are greater than 500 mM),
indicating the importance of the g-butyrolac-
tone pharmacophore in antagonism of QS-
regulated GFP production in E. coli JB525. No
growth inhibitory effects were observed formetabolites 1–3 in either assay at the highest concentrations
tested over 500 mM.
Structurally Modified Honaucin A Derivatives
Within its relatively small structure, honaucin A (1) possesses
three distinct functional groups; an (S)-3-hydroxy-g-butyrolac-
tone, an esterified a,b-unsaturated carboxylate, and a primary
halogen atom (Figure 3A). The g-butyrolactone is a conserved
functional group in AHLs, the primary class of QS molecule in
Gram negative bacterial signaling. Previous efforts to develop
synthetic inhibitors of AHL-mediated QS signaling have mostly
retained the homoserine lactone feature (Lowery et al., 2010).
However, to our knowledge b-hydroxy-g-butyrolactones have
not previously been evaluated for QS inhibition or anti-inflamma-
tory activity. Similarly, although Gershon et al. (1976) assayed
a series of 4-substituted crotonic acid esters for antifungal
activity, this structural moiety and related derivatives have not
been examined for QS-inhibitory or anti-inflammatory activities.
Thus, with the goal of identifying structural features respon-
sible for the anti-inflammatory and QS-inhibitory activities of
the honaucins, we prepared analogs of the subunits forming
the honaucins and then combined these in a systematic fashion.
Modifications included alterations to the configuration and
position of the hydroxy substituent on the g-butyrolactone ring
(46, 1617), presence and position of the double bond, carbon
chain length and nature of the halogen atom in the crotonic acid
portion (715, 1826) (Figure 3C). The resulting analogs were
then assayed in the QS inhibitory and anti-inflammatory assays
(Table 2).
Anti-Inflammatory Activities of Synthetic Honaucin
A Derivatives
Of the three structural subunits representing the lactone
portion, (S)-3-hydroxy-g-butyrolactone (4), (R)-3-hydroxy-g-
butyrolactone (5), and (R/S)-2-hydroxy-g-butyrolactone (6), the
fragment representing natural honaucin A (1) was the mostrved
Table 2. Biological Activities of Natural and Synthetic Honaucin A Derivatives
Compounds
NO Inhibition
(IC50 ± SD
a, mM)
p Values for IC50
Values from NO
Inhibition Compared
to Compound 1
Cell Survival
at IC50 of NO
Inhibition (%)
Cytotoxicity in
Raw264.7 Cells
(IC50, mM)
QS Inhibition (IC50 mM)
V. harveyi E. coli
1 4.0 ± 2.3 100 >49 5.6 38.5
2 4.5 ± 1.0 0.7473 96.8 16 17.6 908
3 7.8 ± 1.4 0.0709 85.2 30 14.6 576
4 21.0 ± 10.8 0.0560 100 >98 –d –d
5 70.7 ± 15.7 0.0019 100 >98 –d –d
6 –b –c –b >98 –d ––d
7 28.0 ± 4.3 0.0010 95.5 80 72.5 152
8 –b –c –b >81 –d –d
9 –b –c –b >116 –d –d
10 –b –c –b >116 –d –d
11 –b –c –b >100 –d –d
12 55.8 ± 5.9 0.0001 95.0 >67 –d –d
13 11.6 ± 4.3 0.0540 100 >288 167 >304
14 3.5 ± 0.5 0.7316 94.7 35 10.5 –e
15 1.2 ± 0.2 0.1036 96.4 10 1.2 –e
16 9.7 ± 3.6 0.0819 80.0 56.5 –d –d
17 39.3 ± 3.7 0.0001 94.0 >49 22.1 260
18 19.6 ± 5.3 0.0015 100 >49 15.9 221
19 –b –c –b >49 –d –d
20 20.8 ± 3.3 0.0019 100 >54 –d –d
21 –b –c –b >59 –d –d
22 –b –c –b >59 –d –d
23 6.2 ± 1.5 0.2375 100 >43 –d –d
24 4.3 ± 0.6 0.8377 85.0 128 168 342
25 1.5 ± 0.0 0.0001 91.7 22 0.24 0.51
26 0.9 ± 0.1 0.0801 100 23 0.13 0.70
aStandard deviation was calculated from three technical replicates.
bNo activity was observed with the compound up to the highest concentration tested (30 mg/ml).
cInhibition of NO production in LPS-stimulated Raw 264.7 cells did not reach to 50% at the highest test concentration (30 mg/ml), and it was not
possible to calculate the p value.
dNo activity was observed with the compound up to the concentration of 125 mg/ml.
eDue to the antibiotic effects of these compounds, their IC50 values could not be reliably measured.
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Structure-Activity Relationships of the Honaucinspotent (IC50 of 4 = 21.0 mM, Table 2; Figure 4A). Both the con-
figuration and position of the hydroxy group in the lactone
moiety are important to the anti-inflammatory potency of these
g-butyrolactones. The second subunit, 4-chlorocrotonic acid
(7), showed modest anti-inflammatory activity by itself (IC50 =
28.0 mM, Table 2; Figure 4B). The chain extended derivative
(12) showed similar activity to 7, whereas modification of the
conjugated double bond of 4-chlorocrotonic acid (8, 10, 11)
significantly decreased anti-inflammatory activity. The inhibition
of NO production by compounds 8, 10, and 11 in LPS-stimu-
lated Raw 264.7 cells did not reach to 50% at the highest test
concentration (30 mg/ml), so their IC50 values could not be
determined. The presence of a halogen atom at C-4 of crotonic
acid (9, 13–15) also led to a dramatic change in anti-inflamma-
tory activity. While crotonic acid (9) displayed no activity up to
116 mM, 4-fluorocrotonic acid (13), 4-bromocrotonic acid (14),
and 4-iodocrotonic acid (15) were potent NO inhibitors withChemistry & Biology 19,IC50 values of 11.6 mM, 3.5 mM, and 1.2 mM, respectively (Table
2; Figure 4C). Therefore, the conjugated double bond and
halogen atom present in the carboxylic acid moiety appear to
be quite important to the anti-inflammatory properties of the
honaucins.
In synthetic analogs of honaucin A containing both the g-
butyrolactone and crotonic acid portions, modifications to the
point of attachment between the two subunits [epi-honaucin A
(17) and 2-hydroxy honaucin A (18)] generally led to less potent
molecules. As shown for compounds 8, 10, and 11, most
modifications (19, 2122) of the double-bond portion of the
4-chlorocrotonic acid moiety of honaucin A resulted in
decreased anti-inflammatory activity, and they did not inhibit
50% NO production in LPS-stimulated murine macrophages
at the highest concentration tested (30 mg/ml). The exception
to this trend was substitution of the halogen atom; 40-bromoho-
naucin A (25) and 40-iodohonaucin A (26) exhibited improved589–598, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 593
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Figure 3. Synthesis of Honaucin A and Its Synthetic Analogs
(A) The two building units of honaucin A (1).
(B) Synthetic scheme of honaucin A and its analogs.
(C) Synthetic honaucin A analogs and their building units.
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0.9 mM, respectively (Table 2; Figure 4D).
Inhibition of QS Phenotypes by Synthetic Analogs of
Honaucin A
The QS-mediated antagonism of V. harveyi bioluminescence by
the naturally occurring analogs honaucins B (2) and C (3) indi-
cated that the butyrolactone functional group was not necessary
for activity. The various g-butyrolactones (46) by themselves
showed no inhibitory activity in either the V. harveyi BB120 or
E. coli JB525 assays, indicating that this moiety by itself was
also not sufficient for QS antagonism (Table 2). By contrast,
the 4-chlorocrotonic acid (7) subunit retained partial inhibitory
activity of V. harveyi bioluminescence with an IC50 of 72.5 mM.
However, modification of the halogen atom at the 4-position
of the crotonic acid fragment greatly modulated QS-inhibitory
activity. While 4-fluorocrotonic acid (13) had decreased inhi-
bitory activity against V. harveyi BB120 (IC50 = 167 mM), the 4-
bromocrotonic acid fragment (14) showed a marked increase
in activity (IC50 = 10.5 mM), and 4-iodocrotonic acid (15) exhibited
a 60-fold increase in activity (IC50 = 1.2 mM) in comparison with
4-chlorocrotonic acid (7). However, it is noteworthy that both 7
and 14 were mildly antibiotic at high concentrations (antibiotic594 Chemistry & Biology 19, 589–598, May 25, 2012 ª2012 Elseviereffects were observed at 14- and 72-fold-greater concentra-
tions, when comparing the minimum inhibitory concentration
(MIC) of growth-inhibitory effects to QS-inhibitory IC50 values,
respectively). The most potent crotonic acid fragment, 15,
showed no growth-inhibitory effects up to 32 mM.
This same trend was observed in the inhibition of GFP pro-
duction by E. coli JB525. 4-Chlorocrotonic acid (7) inhibited
GFP production with an IC50 of 152 mM, while 4-fluorocrotonic
acid (13) was more than 2-fold less active. The brominated and
iodinated analogs (14 and 15) were the most potent, but anti-
biotic effects (MIC = 188 and 18 mM, respectively) precluded
confident measurement of their IC50 concentrations.
Of derivatives containing both core moieties of the honaucins,
3-epi-honaucin A (17) and 2-hydroxy honaucin A (18) were 3- to
4-fold less active than honaucin A against both sensor strains,
suggesting that the 3S attachment represents the optimal posi-
tion and configuration. Halogen substitution had a dramatic
effect on the QS inhibitory activity of the intact honaucin A
analogs (Figure 5). Against V. harveyi, the fluorinated derivative
(24) was 30-fold less potent, whereas the brominated and
iodinated analogs (25 and 26) were an impressive 23- and 43-
fold more active (IC50 = 0.24 mM and 0.13 mM), respectively. A
similar trend was observed against the E. coli JB525 sensorLtd All rights reserved
Figure 4. Inhibition of LPS-Stimulated Production
of NO in Murine Macrophages by Honaucin A
Analogs and Their Structural Units
Error bars indicate the mean ± SD for n = 3.
(A) Inhibition of LPS-stimulated NO production by 1
compared to hydroxy-g-butyrolactones 4–6.
(B) Inhibition of LPS-stimulated NO production by 1
compared to carboxylic acids 7–12.
(C) Inhibition of LPS-stimulated NO production by 1
compared to 4-halogenated crotonic acids 7 and 13–15.
(D) Inhibition of LPS-stimulated NO production by 1
compared to selected honaucin A derivatives 24–26.
See also Figure S5.
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possessed IC50 concentrations of 0.51 mM and 0.70 mM (76-
and 55-fold more active), respectively. Of derivatives containing
both core moieties, antibacterial effects were only observed for
compounds 25 and 26, which only modestly affected bacterial
growth in both assays (MIC = 251 mM and 422 mM, respectively,
against E. coli JB525; MIC = 125 mM and 105 mM, respectively,
against V. harveyi BB120).
DISCUSSION
Structure-Activity Relationships of the Honaucins
Anti-inflammatory andQS-inhibition assay of the naturally occur-
ring honaucins and their synthetic analogs indicated that each of
the functional groups comprising the honaucins is critical for
anti-inflammatory and QS-inhibition activity, with the exception
that the chlorine atom can be substituted with either bromine
or iodine, but not fluorine, and retain high potency. Most modi-
fications to the ring structure, such as the position and con-
figuration of the substitutions on the lactone ring, as well as
the absence of a conjugated double bond or halogenation in
the crotonic acid fragment, decreased activity in both assay
systems (Table 2). Exceptions to these trends were 40-bromoho-
naucin A (25) and 40-iodohonaucin A (26), which both showed
potent anti-inflammatory and QS-inhibitory activities without
appreciable toxicity. Their potency, compared to that of honau-
cin A (1), was increased nearly 30-fold in the QS inhibition and
3- to 5-fold in the anti-inflammatory assay. The correlation of
biological activity with the ease of displacement of the halogen
leaving group suggests that the activity of the honaucins may
involve nucleophilic reactions at C-40. However, inconsistent
with this hypothesis, both 4-fluorocrotonic acid (13) and 40-fluo-
rohonaucin A (24), in which the fluorine atoms are not easily
displaced, showed similar or more potent anti-inflammatory
activities than 4-chlorocrotonic acid (7) or honaucin A (1),
respectively. This suggests that honaucin inhibition of the innate
immune response occurs by mechanisms other than, or in addi-Chemistry & Biology 19, 589–598, May 25tion to, halogen-atom nucleophilic displace-
ment. 40-Iodohonaucin A (26) was the most
active compound among this series of honau-
cins. However, it was found to be quite labile,
presumably through a facile displacement of
the iodine atom, and therefore, 40-bromohonau-
cin A (25) may be the most promising candidate
for further development.Honaucin A (1) displayedmuchmore potent anti-inflammatory
and QS inhibitory activities than either of its active component
fragments, (S)-3-hydroxy g-butyrolactone (4) and 4-chlorocro-
tonic acid (7). These results suggest that a synergism is achieved
when these two structural units are combined within a single
molecule, and it is therefore conceivable that the honaucins
have resulted through an evolutionary process that is conceptu-
ally similar to fragment-based drug design.
Honaucin A and Inhibition of Quorum Sensing
Intraspecies QS in Gram negative bacteria is most commonly
regulated by AHLs (Galloway et al., 2011). Honaucin A is struc-
turally similar to the AHLs, retaining both the g-butyrolactone
and a linear acyl side chain. However, the small structural alter-
ations present in the honaucins appear to modulate their binding
characteristics in such a way that they act as antagonists, rather
than inducers, of QS-regulated phenotypes.
A handful of QS antagonists have been isolated from various
marine organisms (Clark et al., 2008; Dobretsov et al., 2010;
Givskov et al., 1996; Kwan et al., 2010, 2011; Teasdale et al.,
2009, 2011), and four such inhibitors have been previously
isolated from marine cyanobacteria. However, the honaucins
are chemically distinct from each of these. Lyngbyoic acid, iso-
lated from Lyngbya cf. majuscula, modestly inhibited QS in
P. aeruginosa, reducing elastase and pyocyanin produc-
tion (Kwan et al., 2011). The tumonoic acids obtained from
Blennothrix cantharidosmum also showed modest activity, in-
hibiting bioluminescence production in V. harveyi with an IC50
of 62 mM (Clark et al., 2008). Malyngamide C and 8-epi-malyng-
amide C moderately inhibited LasR-based QS in P. aeruginosa
(Kwan et al., 2010). Finally, malyngolide which was obtained
from Lyngbya majuscula, modestly inhibited (IC50 = 110 mM)
the production of violacein, a QS-regulated phenotype in
Chromobacterium violaceum (Dobretsov et al., 2010). In
comparison, honaucins AC are considerably more potent in
their inhibition of V. harveyi-regulated bioluminescence, with
IC50s ranging from 5.6 to 17.6 mM. Furthermore, honaucin, 2012 ª2012 Elsevier Ltd All rights reserved 595
Figure 5. Inhibition of QS Signaling by Honaucin A
and Three of Its Derivatives
Error bars indicate the mean ± SD for n = 3.
(A) Inhibition of QS-signaling phenotype in Vibrio harveyi
BB120.
(B) Inhibition of QS-signaling phenotype in Escherichia coli
JB525.
Honaucin A, 1; 40-Fluorohonaucin A, 24; 40-Bromoho-
naucin A, 25; 40-Iodohonaucin A, 26.
See also Figure S5.
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with an IC50 of 38.5 mM. Together, these results suggest that
honaucin A inhibits AHL-mediated QS pathways, but further
studies will be required to clarify the precise molecular mecha-
nism of action of this new metabolite class.
Honaucin A and Inhibition of Eukaryotic Inflammation
Honaucin A and its brominated and iodinated analogs inhibited
NO production in LPS-stimulated macrophages with IC50s
ranging from 0.8 to 4.0 mM. In addition to their potent biological
activity and modest cytotoxicity, these molecules are small,
structurally concise, and synthetically tractable. These qualities
present the honaucins as attractive potential anti-inflammatory
drug leads.
There is considerable need to develop new anti-inflammatory
treatments that have alternative molecular targets compared to
the more traditional agents, which target cyclooxygenases
(COX) 1 and 2. Many patients are allergic to, or suffer adverse
side effects from, COX inhibitors, limiting their treatment
options (Farooque and Lee, 2009; Sa´nchez-Borges et al.,
2004; Lanas, 2010). While the molecular target of the honaucins
is yet to be identified, continuing efforts are underway to define
the precise mechanism of action for these new modulators of
inflammation.
Quorum-Sensing Inhibition and Anti-Inflammatory
Activity
The honaucins and several of their synthetic analogs were potent
inhibitors of both bacterial QS and NO production by LPS-
stimulated macrophages. These two bioactivities may be
mechanistically related. A scatter plot of these two activities of
the honaucins displayed a positive correlation (Figure S5). Ours
is not the first report of a biomolecule having dual involvement
in QS and inflammation. Kravchenko et al. (2008) observed
attenuated inflammation in activated bone-marrow-derived
macrophages in the presence of the P. aeruginosa QS signaling
molecule N-(3-Oxododecanoyl)-L-homoserine lactone. This
compound was found to exert anti-inflammatory effects by im-
pairing the activation of NF-kB-dependent gene expression.
However, not all accounts describe attenuation of the immune
response; there have also been reports of immune activation
by inhibition of the transcriptional activity of peroxisome-prolifer-
ator-activated receptor gamma (PPARg) (Jahoor et al., 2008;
Cooley et al., 2010; Teplitski et al., 2011). This discrepancy
may be explained by a biphasic role for AHLs in immunomodu-
lation in which they exert anti-inflammatory effects at low596 Chemistry & Biology 19, 589–598, May 25, 2012 ª2012 Elsevierconcentrations and stimulate inflammation at higher concentra-
tions (Hughes and Sperandio, 2008).
Manoalide is another example of a natural product that is a QS
inhibitor and possesses anti-inflammatory properties. The ses-
terpene metabolite, originally isolated from the Indo-Pacific
sponge Luffariella variabilis (de Silva and Scheuer, 1980), was
found to exert anti-inflammatory effects through an irreversible
inhibition of PLA2, as well as antimicrobial activity through
a strong inhibition of QS signaling. This latter activity was
observed in both a promiscuous LuxR-regulated QS system
cloned into E. coli and a P. aeruginosa-specific QS screen
(Skindersoe et al., 2008). Thus, a commonality in the signaling
pathways for prokaryotic QS and eukaryotic inflammation is
potentially responsible for the pleiotropic effects of the honau-
cins and their analogs (Jahoor et al., 2008), a phenomenon
described as ‘‘evolutionary molecular modeling’’(Wink, 2003).
SIGNIFICANCE
Three structurally novel metabolites, honaucins A–C (1–3),
were isolated from the bloom-forming cyanobacterium Lep-
tolyngbya crossbyana and show potent anti-inflammatory
and quorum-sensing (QS) inhibitory properties. Honaucin A
(1) consists of two distinct structural units, (S)-3-hydroxy-
g-butyrolactone and 4-chlorocrotonic acid. In honaucin B
(2), the lactone of honaucin A is opened to form the ethyl
ester and the 4-chlorocrotonic acid is esterified to the C-4
hydroxy group rather than the C-3 hydroxy group as in
honaucin A. Honaucin C (3) was found to be the methyl
ester equivalent of honaucin B (2). These three metabolites
inhibited lipopolysaccharide (LPS)-stimulated nitric oxide
production and repressed expression of proinflammatory
cytokines in murine macrophages. Furthermore, all three
compounds were effective at inhibiting QS signaling-depen-
dent phenotypes in V. harveyi BB120 and E. coli JB525.
Biological screening of synthetic analogs of honaucin
A revealed that the halogen atom at the 4-position of the
crotonic acid subunit was crucial for both anti-inflammatory
and QS inhibitory properties. The analogs 40-bromohonau-
cin A (25) and 40-iodohonaucin A (26) were discovered to
have more potent anti-inflammatory and QS inhibitory
effects compared to the natural honaucins. Due to its
stability and potent biological properties, 40-bromohonaucin
A (25) may represent a valuable lead for the development of
drugs with dual anti-inflammatory and bacterial QS inhibi-
tory properties.Ltd All rights reserved
Chemistry & Biology
Structure-Activity Relationships of the HonaucinsEXPERIMENTAL PROCEDURES
General Experimental Procedures
See Supplemental Experimental Procedures.
Collection and Identification of Marine Cyanobacteria
The colonial cyanobacterium L. crossbyana (HI09-1) was collected in January
2009 by SCUBA from Honaunau reef, Hawai’i, at a depth of 20 m (GPS co-
ordinates N1942.3380, W15591.2920). Samples were stored in 70% EtOH
at 20C prior to extraction. The collected specimen was morphologically
and phylogenetically identified in a previous study (Choi et al., 2010).
Extraction and Isolation
The cyanobacterial tissue was extracted repetitively with 2:1 CH2Cl2-CH3OH
to yield 1.7 g of crude extract. A portion of the extract (1.4 g) was fractionated
by silica gel VLC with a stepped gradient elution of hexanes, EtOAc, and
MeOH. The fraction eluting with 40% hexanes in EtOAc was dried under
reduced pressure, dissolved in hexanes, and extracted with MeOH. The
MeOH-soluble material was fractionated using a Silica Sep-Pak column. The
fraction eluting with 50% hexanes in EtOAc was subsequently subjected to
RP HPLC (Phenomenex Fusion RP 4 m C18, 250 3 10 mm, 50% CH3CN/
H2O at 3 mL/min) to give pure honaucin A (1, 5.4 mg, 0.39%) and honaucin
B (2, 1.4 mg, 0.10%). The fraction eluting with 75% hexanes in EtOAc on Silica
Sep-Pak chromatography was also subjected to RP HPLC (Phenomenex
Fusion RP 4 m C18, 250 3 10 mm, 50% CH3CN/H2O at 3 mL/min) to give
pure honaucin C (3, 1.1 mg, 0.08%).
Honaucin A (1): colorless oil; [a]D
22 80.5 (c 0.2, MeOH); ultraviolet (UV)
(MeCN) lmax 205 nm (log ε 4.17); IR (neat) nmax 3010, 2955, 1784, 1724,
1316, 1270, 1167, 991 cm1; 1H, 13C, and 2D NMR data, see Table 1; HR
ESITOFMS m/z [M + H]+ 205.0262 (calculated for C8H10ClO4 205.0262).
Honaucin B (2): colorless oil; [a]D
22 8.0 (c 0.2, CH2Cl2); UV (MeCN) lmax
206 nm (log ε 4.33); IR (neat) nmax 3454, 2983, 1724, 1659, 1316, 1272, 1182,
1028 cm1; 1H, 13C, and 2D NMR data, see Table 1; HR ESITOFMS m/z
[M + Na]+ 273.0499 (calculated for C10H15ClNaO5 273.0500).
Honaucin C (3): colorless oil; [a]D
22 8.7 (c 0.2, CH2Cl2); UV (MeCN) lmax
206 nm (log ε 4.31); IR (neat) nmax 3451, 2982, 1724, 1659, 1316, 1272,
1182, 1029 cm1; 1H and 13C NMR data, see Table 1; HR ESITOFMS m/z
[M + Na]+ 259.0346 (calculated for C9H13Cl NaO5 259.0344).
Preparation of Synthetic Honaucin A and Its Analogs
See Supplemental Experimental Procedures for preparation and analytical
data of synthetic honaucin A and its analogs.
Assay for the Detection of NO Production by Murine Macrophages
Measurement of NO production by murine macrophages stimulated with lipo-
polysaccharide, in the presence and absence of natural products and
synthetic analogs, followed our previously published procedures (Villa et al.,
2010). This process is described in detail in the Supplemental Experimental
Procedures.
Assessment of the Antioxidant Capacity of Honaucin A
See Supplemental Experimental Procedures for a detailed experimental
description of assessment of the antioxidant capacity of honaucin A.
RNA Isolation and cDNA Synthesis
See Supplemental Experimental Procedures for a detailed experimental
description of RNA isolation and cDNA synthesis.
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction of cDNA isolated from
cells treated with honaucin A or other experimental conditions followed estab-
lished protocols that are given in detail in the Supplemental Experimental
Procedures.
Quorum-Sensing Reporter Strains and Assays
Quorum-sensing assays were run in two microbial systems, V. harveyi BB120
(Bassler et al., 1997), a wild-type, bioluminescent strain, and Escherichia coliChemistry & Biology 19,JB525 (E. coli MT102 harboring the gfp plasmid pJBA132), which produces
an unstable GFP in response to C6-C8 AHL autoinducers (Andersen et al.,
2001). Detailed descriptions of the experimental protocols are given in the
Supplemental Experimental Procedures.
Statistics
All experiments included three replicates. Data are presented as the mean ±
SD for the indicated number of technical replicates. Student’s t test was
used for the determination of statistical significance, with p < 0.05 being
considered significant. Prism software (Graphpad Software Inc., San Diego,
CA) was used to generate figure graphs displaying SD.
ACCESSION NUMBERS
The 16S rRNA gene sequence of L. crossbyana is available in the DDBJ/EMBL/
GenBank databases under accession number GU111930.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.chembiol.2012.03.014.
ACKNOWLEDGMENTS
We gratefully acknowledge support of this research from UC San Diego and
NIH NS053398. We thank the B.S. Moore laboratory (UCSD) for a sample of
4-fluorocrotonic acid.
Received: January 20, 2012
Revised: March 23, 2012
Accepted: March 27, 2012
Published: May 24, 2012
REFERENCES
Andersen, J.B., Heydorn, A., Hentzer, M., Eberl, L., Geisenberger, O.,
Christensen, B.B., Molin, S., and Givskov, M. (2001). gfp-based N-acyl homo-
serine-lactone sensor systems for detection of bacterial communication. Appl.
Environ. Microbiol. 67, 575–585.
Bassler, B.L., Greenberg, E.P., and Stevens, A.M. (1997). Cross-species
induction of luminescence in the quorum-sensing bacterium Vibrio harveyi.
J. Bacteriol. 179, 4043–4045.
Cheung, K.P., Taylor, K.R., and Jameson, J.M. (2011). Immunomodulation at
epithelial sites by obesity and metabolic disease. Immunol. Res., in press.
Published online December 13, 2011. 10.1007/s12026-011-8261-7.
Choi, H., Engene, N., Smith, J.E., Preskitt, L.B., and Gerwick, W.H. (2010).
Crossbyanols A-D, toxic brominated polyphenyl ethers from the Hawai’ian
bloom-forming Cyanobacterium Leptolyngbya crossbyana. J. Nat. Prod. 73,
517–522.
Clark, B.R., Engene, N., Teasdale, M.E., Rowley, D.C., Matainaho, T.,
Valeriote, F.A., and Gerwick, W.H. (2008). Natural products chemistry and
taxonomy of the marine cyanobacterium Blennothrix cantharidosmum.
J. Nat. Prod. 71, 1530–1537.
Conaghan, P.G. (2011). A turbulent decade for NSAIDs: update on current
concepts of classification, epidemiology, comparative efficacy, and toxicity.
Rheumatol. Int. 10.1007/s00296-011-2263-6.
Cooley, M.A., Whittall, C., and Rolph, M.S. (2010). Pseudomonas signal mole-
cule 3-oxo-C12-homoserine lactone interferes with binding of rosiglitazone to
human PPARgamma. Microbes Infect. 12, 231–237.
de Silva, E.D., and Scheuer, P.J. (1980). Manoalide, an antibiotic sesterterpe-
noid from the marine sponge Luffariella variabilis. Tetrahedron Lett. 21, 1611–
1614.
Dobretsov, S., Teplitski, M., Alagely, A., Gunasekera, S.P., and Paul, V.J.
(2010). Malyngolide from the cyanobacterium Lyngbya majuscula interferes
with quorum sensing circuitry. Environ. Microbiol. Rep. 2, 739–744.589–598, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 597
Chemistry & Biology
Structure-Activity Relationships of the HonaucinsFarooque, S.P., and Lee, T.H. (2009). Aspirin-sensitive respiratory disease.
Annu. Rev. Physiol. 71, 465–487.
Flachsmann, F., Schellhaas, K., Moya, C.E., Jacobs, R.S., and Fenical, W.
(2010). Synthetic pseudopterosin analogues: a novel class of antiinflammatory
drug candidates. Bioorg. Med. Chem. 18, 8324–8333.
Freeman, J.A., Lilley, B.N., and Bassler, B.L. (2000). A genetic analysis of the
functions of LuxN: a two-component hybrid sensor kinase that regulates
quorum sensing in Vibrio harveyi. Mol. Microbiol. 35, 139–149.
Galloway, W.R.D.J., Hodgkinson, J.T., Bowden, S.D., Welch, M., and Spring,
D.R. (2011). Quorumsensing inGram-negative bacteria: small-moleculemodu-
lation of AHL and AI-2 quorum sensing pathways. Chem. Rev. 111, 28–67.
Gautam, R., and Jachak, S.M. (2009). Recent developments in anti-inflamma-
tory natural products. Med. Res. Rev. 29, 767–820.
Gershon, H., Shanks, L., and Gawiak, D.E. (1976). Antifungal activity of 4-
substituted crotonic acid esters. J. Med. Chem. 19, 1069–1072.
Givskov, M., de Nys, R., Manefield, M., Gram, L., Maximilien, R., Eberl, L.,
Molin, S., Steinberg, P.D., and Kjelleberg, S. (1996). Eukaryotic interference
with homoserine lactone-mediated prokaryotic signalling. J. Bacteriol. 178,
6618–6622.
Grivennikov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inflammation,
and cancer. Cell 140, 883–899.
Henke, J.M., and Bassler, B.L. (2004). Three parallel quorum-sensing systems
regulate gene expression in Vibrio harveyi. J. Bacteriol. 186, 6902–6914.
Hughes, D.T., and Sperandio, V. (2008). Inter-kingdom signalling: communica-
tion between bacteria and their hosts. Nat. Rev. Microbiol. 6, 111–120.
Jahoor, A., Patel, R., Bryan, A., Do, C., Krier, J., Watters, C., Wahli, W., Li, G.,
Williams, S.C., and Rumbaugh, K.P. (2008). Peroxisome proliferator-activated
receptors mediate host cell proinflammatory responses to Pseudomonas aer-
uginosa autoinducer. J. Bacteriol. 190, 4408–4415.
Kravchenko, V.V., Kaufmann, G.F., Mathison, J.C., Scott, D.A., Katz, A.Z.,
Grauer, D.C., Lehmann, M., Meijler, M.M., Janda, K.D., and Ulevitch, R.J.
(2008). Modulation of gene expression via disruption of NF-kB signaling by
a bacterial small molecule. Science 321, 259–263.
Kwan, J.C., Teplitski, M., Gunasekera, S.P., Paul, V.J., and Luesch, H. (2010).
Isolation and biological evaluation of 8-epi-malyngamide C from the Floridian
marine cyanobacterium Lyngbya majuscula. J. Nat. Prod. 73, 463–466.
Kwan, J.C.,Meickle, T., Ladwa,D., Teplitski,M., Paul, V., andLuesch,H. (2011).
Lyngbyoic acid, a ‘‘tagged’’ fatty acid from a marine cyanobacterium, disrupts
quorum sensing in Pseudomonas aeruginosa. Mol. Biosyst. 7, 1205–1216.
Lanas, A. (2010). A review of the gastrointestinal safety data—a gastroenterol-
ogist’s perspective. Rheumatology (Oxford) 49 (Suppl 2 ), ii3–ii10.
Lowery, C.A., Salzameda, N.T., Sawada, D., Kaufmann, G.F., and Janda, K.D.
(2010). Medicinal chemistry as a conduit for themodulation of quorum sensing.
J. Med. Chem. 53, 7467–7489.
McFall-Ngai, M., Nyholm, S.V., and Castillo, M.G. (2010). The role of the
immune system in the initiation and persistence of the Euprymna scolopes—
Vibrio fischeri symbiosis. Semin. Immunol. 22, 48–53.
Moghadam-Kia, S., and Werth, V.P. (2010). Prevention and treatment of
systemic glucocorticoid side effects. Int. J. Dermatol. 49, 239–248.
Nagle, D.G., and Paul, V.J. (1999). Production of secondarymetabolites by fila-
mentous tropical marine cyanobacteria: ecological functions of the
compounds. J. Phycol. 35, 1412–1421.
Ni, N., Choudhary, G., Peng, H., Li, M., Chou, H.-T., Lu, C.-D., Gilbert, E.S., and
Wang, B. (2009). Inhibition of quorum sensing in Vibrio harveyi by boronic
acids. Chem. Biol. Drug Des. 74, 51–56.
Ogier, J.C., Calteau, A., Forst, S., Goodrich-Blair, H., Roche, D., Rouy, Z.,
Suen, G., Zumbihl, R., Givaudan, A., Tailliez, P., et al. (2010). Units of plasticity
in bacterial genomes: new insight from the comparative genomics of two
bacteria interacting with invertebrates, Photorhabdus and Xenorhabdus.
BMC Genomics 11, 568.
Pappas, K.M., and Winans, S.C. (2003). A LuxR-type regulator from
Agrobacterium tumefaciens elevates Ti plasmid copy number by activating
transcription of plasmid replication genes. Mol. Microbiol. 48, 1059–1073.598 Chemistry & Biology 19, 589–598, May 25, 2012 ª2012 ElsevierPrasad, K., Chen, K.-M., Repic, O., and Hardtmann, G.E. (1990). A highly
stereoselective route to the four stereoisomers of a six-carbon synthon.
Tetrahedron Asymmetry 1, 307–310.
Rumbaugh, K.P., and Kaufmann, G.F. (2012). Exploitation of host signaling
pathways by microbial quorum sensing signals. Curr. Opin. Microbiol. 15,
162–168. Published online December 26, 2011. 10.1016/j.mib.2011.12.003.
Sa´nchez-Borges, M., Capriles-Behrens, E., and Caballero-Fonseca, F. (2004).
Hypersensitivity to non-steroidal anti-inflammatory drugs in childhood.
Pediatr. Allergy Immunol. 15, 376–380.
Skindersoe, M.E., Ettinger-Epstein, P., Rasmussen, T.B., Bjarnsholt, T., de
Nys, R., and Givskov, M. (2008). Quorum sensing antagonism from marine
organisms. Mar. Biotechnol. (NY) 10, 56–63.
Smith, J.E., Kuwabara, J., Flanaga, K., duPlessis, S., Coney, J., Beets, J.,
Takabayashi, M., Barnes, S., Turner, J., Brown, D., et al. (2008). An unusual cy-
anobacterial bloom in Hawai’i. Coral Reefs 27, 851.
Swem, L.R., Swem, D.L., Wingreen, N.S., and Bassler, B.L. (2008). Deducing
receptor signaling parameters from in vivo analysis: LuxN/AI-1 quorum
sensing in Vibrio harveyi. Cell 134, 461–473.
Swem, L.R., Swem, D.L., O’Loughlin, C.T., Gatmaitan, R., Zhao, B., Ulrich,
S.M., and Bassler, B.L. (2009). A quorum-sensing antagonist targets both
membrane-bound and cytoplasmic receptors and controls bacterial pathoge-
nicity. Mol. Cell 35, 143–153.
Teasdale, M.E., Liu, J., Wallace, J., Akhlaghi, F., and Rowley, D.C. (2009).
Secondarymetabolites produced by themarine bacteriumHalobacillus salinus
that inhibit quorum sensing-controlled phenotypes in gram-negative bacteria.
Appl. Environ. Microbiol. 75, 567–572.
Teasdale, M.E., Donovan, K.A., Forschner-Dancause, S.R., and Rowley, D.C.
(2011). Gram-positivemarine bacteria as a potential resource for the discovery
of quorum sensing inhibitors. Mar. Biotechnol. (NY). 13, 722–732. Published
online December 9, 2010. 10.1007/s10126-010-9334-7.
Teng, S.-W., Schaffer, J.N., Tu, K.C., Mehta, P., Lu, W., Ong, N.P., Bassler,
B.L., and Wingreen, N.S. (2011). Active regulation of receptor ratios controls
integration of quorum-sensing signals in Vibrio harveyi. Mol. Syst. Biol. 7,
491. 10.1038/msb.2011.30.
Teplitski, M., Mathesius, U., and Rumbaugh, K.P. (2011). Perception and
degradation of N-acyl homoserine lactone quorum sensing signals by
mammalian and plant cells. Chem. Rev. 111, 100–116.
Terracciano, S., Aquino, M., Rodriquez, M., Monti, M.C., Casapullo, A., Riccio,
R., and Gomez-Paloma, L. (2006). Chemistry and biology of anti-inflammatory
marine natural products: molecules interfering with cyclooxygenase, NF-
kappaB and other unidentified targets. Curr. Med. Chem. 13, 1947–1969.
Tousoulis, D., Kampoli, A.M., Papageorgiou, N., Androulakis, E., Antoniades,
C., Toutouzas, K., and Stefanadis, C. (2011). Pathophysiology of atheroscle-
rosis: the role of inflammation. Curr. Pharm. Des. 17, 4089–4110.
Tidgewell, K.,Clark, B.T., andGerwick,W.H. (2010). The natural products chem-
istry of cyanobacteria. In Comprehensive Natural Products Chemistry, Second
Edition, B. Moore and P. Crews, eds. (Oxford, UK: Elsevier), pp. 141–188.
Uchikawa, O., Okukado, N., Sakata, T., Arase, K., and Terada, K. (1988).
Synthesis of (S)- and (R)-3-hydroxy-4-butanolide and (2S,4S)-, (2R,4S)-,
(2S,4R)-, and (2R,4R)-2-hydroxy-4-hydroxymethyl-4-butanolide and their
satiety and hungermodulating activities. Bull. Chem. Soc. Jpn. 61, 2025–2029.
Villa, F.A., and Gerwick, L. (2010). Marine natural product drug discovery:
Leads for treatment of inflammation, cancer, infections, and neurological
disorders. Immunopharmacol. Immunotoxicol. 32, 228–237.
Villa, F.A., Lieske, K., and Gerwick, L. (2010). Selective MyD88-dependent
pathway inhibition by the cyanobacterial natural product malyngamide F
acetate. Eur. J. Pharmacol. 629, 140–146.
Wink, M. (2003). Evolution of secondary metabolites from an ecological and
molecular phylogenetic perspective. Phytochemistry 64, 3–19.
Zhang, R.G., Pappas, K.M., Brace, J.L., Miller, P.C., Oulmassov, T.,
Molyneaux, J.M., Anderson, J.C., Bashkin, J.K., Winans, S.C., and
Joachimiak, A. (2002). Structure of a bacterial quorum-sensing transcription
factor complexed with pheromone and DNA. Nature 417, 971–974.Ltd All rights reserved
